Theo de Witte

Theo de Witte

UNVERIFIED PROFILE

Are you Theo de Witte?   Register this Author

Register author
Theo de Witte

Theo de Witte

Publications by authors named "Theo de Witte"

Are you Theo de Witte?   Register this Author

100Publications

3909Reads

31Profile Views

Effective oral hypomethylating drugs in intermediate-risk or high-risk myelodysplasia: a breakthrough?

Authors:
Theo de Witte

Lancet Haematol 2019 04;6(4):e170-e171

Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30025-0DOI Listing
April 2019

Dynamic prediction of cumulative incidence functions by direct binomial regression.

Biom J 2018 07 25;60(4):734-747. Epub 2018 Mar 25.

Radboud University Medical Center, Radboud Institute of Molecular Life Sciences, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bimj.201700194DOI Listing
July 2018

Elevated serum ferritin is not specific for hemophagocytic lymphohistiocytosis.

Ann Hematol 2017 Oct 31;96(10):1667-1672. Epub 2017 Jul 31.

Department of Pathology and Immunology, Washington University School of Medicine, 660 S. Euclid Ave, Campus Box 8118, St. Louis, MO, 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-017-3072-0DOI Listing
October 2017

Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients.

PLoS One 2016 30;11(11):e0165582. Epub 2016 Nov 30.

Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0165582PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130187PMC
September 2017

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

N Engl J Med 2017 08 23;377(5):454-464. Epub 2017 Jun 23.

From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (R.M.S.); the Division of Biomedical Statistics and Informatics (S.J.M., K.L.) and the Alliance Statistics and Data Center (S.J.M., K.L., S.G.), Mayo Clinic, Rochester, MN; the Alliance Statistics and Data Center, Duke University, Durham, NC (B.L.S.); the Ohio State University Comprehensive Cancer Center, Columbus (S.G., C.D.B., T.W.P., G.M., R.B.K.); Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden (C.T., G.E.), Department of Internal Medicine III, University Hospital of Ulm, Ulm (K.D., R.F.S., H.D.), Hematology and Oncology, University of Leipzig, Leipzig (D.N.), Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover (J.K., A.G.), and Department of Medicine II, Hematology-Oncology, Goethe University Hospital Frankfurt, Frankfurt am Main (H.S.) - all in Germany; the Department of Biomedicine and Prevention, University Tor Vergata, Rome (F.L.-C., S.A.); the Department of Clinical Haematology, Alfred Hospital and Monash University, Melbourne, VIC, Australia (A.W.); Hospital de la Santa Creu i Sant Pau, Hematology Department, Autonomous University of Barcelona, Barcelona (J.S.), and Hospital Universitario la Fe, Hematology Department, Department of Medicine, University of Valencia, Valencia (M.A.S.) - both in Spain; the Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto (J.M.B.); Radboud Institute Molecular Studies, Radboud University Medical Center, Nijmegen, the Netherlands (T.W.); the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (F.R.A.); the Division of Hematology-Oncology, Stanford Comprehensive Cancer Center, Stanford University, Stanford, CA (B.C.M.); the Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (M.S.T.); and the Department of Medicine, University of Chicago, Chicago (R.A.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1614359DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754190PMC
August 2017

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).

J Clin Oncol 2017 Jul 2;35(19):2157-2164. Epub 2017 May 2.

Nicolaus Kröger, University Medical Center Hamburg-Eppendorf, Hamburg; Georg-Nikolaus Franke, University Hospital Leipzig, Leipzig; Uwe Platzbecker, University Hospital Dresden, Dresden; Kai Hübel and Christof Scheid, University of Cologne, Cologne; Thomas Weber, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle; Matthias Stelljes, University of Münster, Münster; Peter Dreger, University of Heidelberg, Heidelberg; Andreas Günther, University Hospital Schleswig Holstein Campus Kiel, Kiel; Wolfgang Bethge, University Hospital Tübingen, Tübingen; Guido Kobbe, Heinrich Heine University, Düsseldorf, Germany; Simona Iacobelli, Università Tor Vergata, Rome; Giorgio Lambertenghi Deliliers and Francesco Onida, Fondazione IRCC Ca' Granda Ospedale Maggiore Policlinico, University of Milano, Milan; Massimo Pini, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria; Stefano Guidi, Azienda Ospedaliera Universitaria Careggi, Florence, Italy; Ruzena Uddin, Guy's Hospital, London, United Kingdom; Marie Robin, Hôpital Saint Louis, Assistance Publique Hôpitaux Paris, France; Boris Afanasyev, SPB Pavlov Medical University, St Petersburg, Russia; Dominik Heim, University Hospital Basel, Basel Switzerland; Liisa Volin, Helsinki University Hospital, Helsiniki, Finland; Xavier Poiré, Cliniques Universitaires St-Luc, Brussels, Belgium; Marleen van Os, European Group of Blood and Marrow Transplantation Clinical Trials Office; Ronald Brand, Leiden University Medical Center, Leiden; and Theo de Witte, Radboud University Medical Center, Nijmegen, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.7349DOI Listing
July 2017

The optimal dosing of gemtuzumab ozagamicin: where to go from here?

Haematologica 2016 06 31;101(6):653-4. Epub 2016 May 31.

Tor Vergata University Hospital, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2016.145763DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013949PMC
June 2016

Allogeneic stem cell transplantation in a patient with myelodysplastic syndrome and polyarteritis nodosa: a case report and systematic review.

Ann Hematol 2016 Mar 20;95(4):645-7. Epub 2016 Jan 20.

Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-015-2587-5DOI Listing
March 2016

New insights into transfusion-related iron toxicity: Implications for the oncologist.

Crit Rev Oncol Hematol 2016 Mar 27;99:261-71. Epub 2015 Nov 27.

Heinrich-Heine-Universität, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2015.11.017DOI Listing
March 2016

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.

J Clin Oncol 2016 Mar 25;34(9):972-9. Epub 2016 Jan 25.

Sergio Amadori, Adriano Venditti, and Maria Teresa Voso, Tor Vergata University; Luciana Annino, San Giovanni Addolorata Hospital; Paolo De Fabritiis, St Eugenio Hospital; Giuliana Alimena and Marco Mancini, Sapienza University; Francesca Paoloni, Marco Vignetti, and Paola Fazi, GIMEMA Foundation, Roma; Franco Aversa, University Hospital, Parma; Gainluca Gaidano, University of Eastern Piedmont, Novara; Maurizio Musso, La Maddalena Clinic, Palermo; Carla Mazzone, Annunziata Hospital, Cosenza; Domenico Magro, Pugliese-Ciaccio Hospital, Catanzaro; Safaa Mahmoud Ramadan, European Institute of Oncology, Milano, Italy; Stefan Suciu and Liv Meert, EORTC Headquarters, Brussels; Dominik Selleslag, AZ St Jan, Brugge; Anne Hagemeijer, KULeuven, Leuven; Frédéric Baron, Centre Hospitalier Universitaire, Liège, Belgium; Petra Muus and Theo de Witte, Radboudumc, Nijmegen; and Roel Willemze, University Medical Center, Leiden, the Netherlands.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/01/21/JCO.2015.64
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.64.0060
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.64.0060DOI Listing
March 2016

Characterization of acute myeloid leukemia based on levels of global hydroxymethylation.

Blood 2014 Aug 1;124(7):1110-8. Epub 2014 Jul 1.

Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-08-518514DOI Listing
August 2014

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

J Clin Oncol 2014 Jan 2;32(3):219-28. Epub 2013 Dec 2.

Roelof Willemze, Constantijn J.M. Halkes, and Erik W.A. Marijt, Leiden University Medical Center, Leiden; Petra Muus, Joop Jansen, and Theo de Witte, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands; Stefan Suciu and Liv Meert, European Organisation for Research and Treatment of Cancer Headquarters; Dominique Bron, Hôpital Universitaire, Bordet-Erasme, Brussels; Dominik L.D. Selleslag, Algemeen Ziekenhuis Sint-Jan, Brugge; Zwi Berneman, Universitair Ziekenhuis, Antwerpen; Georges Fillet, Centre Hospitalier Universitaire du Sart-Tilman, Liège; Anne Hagemeijer, Center for Human Genetics, University of Leuven, Leuven, Belgium; Giovanna Meloni, Marco Mancini, Silvia Maria Trisolini, and Franco Mandelli, "Sapienza" University; Sergio Amadori and Adriano Venditti, Tor Vergata University Hospital; Simona Sica, Università Cattolica del Sacro Cuore, Policlinico A. Gemelli; Paola Fazi and Marco Vignetti, Gruppo Italiano Malattie Ematologiche dell' Adulto Foundation, Central Office, Rome; Giorgina Specchia, Università degli Studi di Bari, Bari; Francesco Fabbiano, Ospedali Riuniti "Villa Sofia-Cervello"; Maria Enza Mitra, Policlinico "Paolo Giaccone," Palermo; Francesco Nobile, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria; Marco Sborgia, Azienda Unitá Sanitaria Locale di Pescara, Pescara; Andrea Camera, L'A.O. Universitaria-Università degli Studi di Napoli "Federico II," Napoli; Domenico Magro, A.O. Pugliese Ciaccio, Catanzaro; Nicola Cantore, A.O. San Giuseppe Moscati, Avellino; Lorella Melillo, Istituto Di Ricovero e Cura a Carattere Scientifico Casa Sollievo della Sofferenza, San Giovanni Rotondo; Pietro Leoni, A.O. Nuovo Ospedale Torrette, Ancona; Mario Luppi, A.O. Universitaria di Modena, Modena; Daniela Cilloni, University of Torino, Torino, Italy; Boris Labar, University Hospital Center-Rebro, Zagreb, Croatia; Jean-Pierre Marie, Saint-Antoine Hospital, Assistance Publique-Hopitaux de Paris and University Paris 6; Francois Lef

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.8571DOI Listing
January 2014

Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).

J Clin Oncol 2013 Dec 14;31(35):4424-30. Epub 2013 Oct 14.

Sergio Amadori and Adriano Venditti, Tor Vergata University Hospital; Paolo De Fabritiis, St Eugenio Hospital; Roberto Latagliata, University Sapienza; Paola Fazi and Marco Vignetti, Gruppo Italiano Malattie Ematologiche dell'Adulto, Roma; Franca Falzetti, University Hospital, Perugia; Domenico Magro, Pugliese Hospital, Catanzaro; Giorgina Specchia, University Hospital, Bari, Italy; Stefan Suciu and Matthias Karrasch, European Organisation for Research and Treatment of Cancer, Brussels; Dominik Selleslag, Algemeen Ziekenhuis St Jan, Brugge; Zwi Berneman, University Hospital, Antwerp, Belgium; Roberto Stasi, St George's Hospital, London, United Kingdom; Helmut R. Salih, University Hospital, Tubingen; Anthony D. Ho, University Hospital, Heidelberg; Michael Lübbert, Albert Ludwigs University, Freiburg, Germany; Petra Muus and Theo de Witte, Radboud University Medical Centre, Nijmegen; Constantijn J.M. Halkes and Roel Willemze, University Medical Center, Leiden, the Netherlands; Xavier Thomas, Edouard Herriot Hospital, Lyon; Jean-Pierre Marie, St. Antoine Hospital, Paris, France; and José E. Guimaraes, University Hospital, Porto, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.0771DOI Listing
December 2013

Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival?

Authors:
Theo de Witte

Leuk Res 2013 Dec 23;37(12):1605. Epub 2013 Sep 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.09.016DOI Listing
December 2013

Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.

Cancer Immunol Immunother 2013 Aug 2;62(8):1381-92. Epub 2013 Jun 2.

Laboratory of Hematology, Department of Laboratory Medicine, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s00262-013-1438
Web Search
http://link.springer.com/10.1007/s00262-013-1438-2
Publisher Site
http://dx.doi.org/10.1007/s00262-013-1438-2DOI Listing
August 2013

Competing risks in epidemiology: possibilities and pitfalls.

Int J Epidemiol 2012 Jun 9;41(3):861-70. Epub 2012 Jan 9.

Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ije/dyr213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396320PMC
June 2012

Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure?

Authors:
Theo de Witte

Clin Lymphoma Myeloma Leuk 2011 Jun 7;11 Suppl 1:S46-8. Epub 2011 May 7.

Department of Tumor Immunology, Nijmegen Centre for Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2011.04.003DOI Listing
June 2011

siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.

Blood 2010 Nov 3;116(22):4501-11. Epub 2010 Aug 3.

Department of Laboratory Medicine-Laboratory of Hematology, Radboud University NijmegenMedical Center, Nijmegen Center for Molecular Life Sciences, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-04-278739DOI Listing
November 2010

Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells.

BMC Pharmacol 2010 Sep 13;10:12. Epub 2010 Sep 13.

Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Nijmegen Medical Centre/Nijmegen Centre for Molecular Life Sciences, Geert Grooteplein 8, 6525GA Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://bmcpharma.biomedcentral.com/articles/10.1186/1471-221
Publisher Site
http://dx.doi.org/10.1186/1471-2210-10-12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945345PMC
September 2010

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.

Nat Genet 2010 Aug 4;42(8):665-7. Epub 2010 Jul 4.

Department of Laboratory Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.620DOI Listing
August 2010

An alternatively spliced CXCL16 isoform expressed by dendritic cells is a secreted chemoattractant for CXCR6+ cells.

J Leukoc Biol 2010 Jun 24;87(6):1029-39. Epub 2010 Feb 24.

Laboratory Medicine, Laboratory of Hematology and Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1189/jlb.0709482
Publisher Site
http://dx.doi.org/10.1189/jlb.0709482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210559PMC
June 2010

Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome.

Br J Haematol 2010 May 11;149(3):322-33. Epub 2010 Jan 11.

Departments of Haematology, adboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2009.08051.xDOI Listing
May 2010

Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome.

Blood 2009 Dec 14;114(27):5512-21. Epub 2009 Oct 14.

Central Hematology Laboratory and Department of Hematology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2009-02-204834DOI Listing
December 2009